Duration of Antiplatelet Therapy After Ischemic Stroke
For noncardioembolic ischemic stroke, antiplatelet therapy should be continued lifelong for secondary prevention, with the specific regimen depending on stroke severity and timing. 1
Initial Dual Antiplatelet Therapy (DAPT) Period
Minor Stroke or High-Risk TIA
For patients with minor ischemic stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4), initiate DAPT (aspirin plus clopidogrel) within 12-24 hours of symptom onset and continue for 21 to 90 days, then transition to single antiplatelet therapy (SAPT) indefinitely. 1
The evidence strongly supports this approach:
The optimal benefit-to-risk ratio occurs in the first week (12.87), declining sharply in weeks 2-3 (1.68) 2. This temporal analysis demonstrates that ischemic protection is concentrated early, while bleeding risk persists.
DAPT initiated within 72 hours reduces new stroke risk (7.3% vs 9.2%, HR 0.79) but increases moderate-to-severe bleeding (0.9% vs 0.4%, HR 2.08) 3
Extending DAPT beyond 90 days is associated with excess hemorrhage risk without additional ischemic benefit 1
Moderate Stroke
For patients with NIHSS ≤5, high-risk TIA (ABCD2 ≥6), or symptomatic stenosis ≥30%, ticagrelor plus aspirin for 30 days may be considered, though this increases serious bleeding including intracranial hemorrhage 1
Post-Mechanical Thrombectomy
For patients undergoing mechanical thrombectomy, 3-month DAPT reduces stroke recurrence compared to 1-month DAPT (lower recurrence rate) without increasing mortality or symptomatic intracranial hemorrhage 4
Long-Term Maintenance Therapy
After completing the initial DAPT period, transition to lifelong single antiplatelet therapy with one of the following 1:
- Aspirin 50-325 mg daily
- Clopidogrel 75 mg daily
- Aspirin 25 mg plus extended-release dipyridamole 200 mg twice daily
Critical Pitfalls to Avoid
- Do not continue DAPT beyond 90 days - this significantly increases hemorrhage risk without reducing ischemic events 1
- Do not use triple antiplatelet therapy - associated with excess bleeding 1
- Do not discontinue antiplatelet therapy entirely - lifelong treatment is indicated for secondary prevention 5
Special Consideration
For patients already on aspirin at the time of stroke, the effectiveness of increasing aspirin dose or switching agents is not well established 1. However, the general principle of lifelong antiplatelet therapy still applies.
The key algorithmic approach is: DAPT for 21-90 days → transition to SAPT indefinitely. The bleeding risk increases in parallel with ischemic risk, so antiplatelet therapy cannot be individualized based solely on bleeding risk assessment - the ischemic benefit consistently outweighs bleeding risk across all risk strata 5.